Rosetta Genomics Completes Acquisition of Parkway Clinical Laborat...(r rates of severe or fatal hemorrha...)

hemorrhage among patients with squamous NSCLC histology compared with

non-squamous NSCLC. In addition, several other targeted drugs for NSCLC

currently under development may require this sensitive differentiation.

- Differentiating mesothelioma from adenocarcinoma - This

differentiation is critical for optimal therapy, but is often difficult

to perform. Currently, there is no objective, standardized test to aid

pathologists in differentiating between the many possible tumors in

the lung and pleura. Based on several microRNA biomarkers, this test

is designed to separate mesothelioma from adenocarcinoma tumors

including lung adenocarcinoma and metastases to the lung or to the

pleura.

- Identifying origin of metastases (CUP) - In 3%-5% of all new

cancer patients, clinicians cannot identify the origin of a patients'

tumor. This information is crucial for determining treatment type. As

demonstrated in a paper published by Rosetta Genomics and

collaborators in the April issue of Nature Biotechnology, Rosetta

Genomics has developed a panel of microRNA biomarkers potentially able

to identify approximately thirty cancer types. This test is designed

to assist clinicians to accurately identify the origin of tumors.

In addition, the company expects the following three tests to enter development during 2009-2010: response prediction to ovarian cancer treatment, predicting risk of gastric cancer recurrence, and differentiation of small cell from non-small cell lung cancer.

About MicroRNA

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate pr
'/>"/>